- Conditions
- Refractive Error, Cataract, Maculopathy
- Interventions
- Not listed
- Lead sponsor
- Sinclair Technologies, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 150 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Elkins Park, Pennsylvania
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 289–312
of 838
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Retinitis Pigmentosa, Usher Syndrome Type 2, Deaf Blind, Retinal Disease, Eye Diseases, Eye Diseases, Hereditary, Eye Disorders Congenital, Vision Disorders
- Interventions
- Ultevursen, Sham-procedure
- Drug · Other
- Lead sponsor
- Laboratoires Thea
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 7 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Miami, Florida + 7 more
- Conditions
- Diabetic Retinopathy, DR, Diabetic Mellitus
- Interventions
- AEYE-DS Software
- Device
- Lead sponsor
- AEYE Health Inc
- Industry
- Eligibility
- 22 Years and older
- Enrollment
- 601 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Choroidal Neovascularization, Macular Degeneration
- Interventions
- Verteporfin, Bevacizumab
- Drug
- Lead sponsor
- Retinal Consultants Medical Group
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2006
- U.S. locations
- 1
- States / cities
- Sacramento, California
- Conditions
- Age Related Macular Degeneration
- Interventions
- RBM-007 Injectable Solution
- Drug
- Lead sponsor
- Maturi, Raj K., M.D., P.C.
- Individual
- Eligibility
- 50 Years to 99 Years
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Indianapolis, Indiana
- Conditions
- Retinitis Pigmentosa 11, Retinal Degeneration, Retinal Disease, Eye Diseases Hereditary, Retinal Dystrophies
- Interventions
- VP-001
- Drug
- Lead sponsor
- PYC Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2028
- U.S. locations
- 6
- States / cities
- Jacksonville, Florida • Miami, Florida • Ann Arbor, Michigan + 3 more
- Conditions
- Neovascular Age-related Macular Degeneration, Age-Related Macular Degeneration, Wet Macular Degeneration
- Interventions
- bevacizumab, ranibizumab
- Biological
- Lead sponsor
- Outlook Therapeutics, Inc.
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 400 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024
- U.S. locations
- 61
- States / cities
- Arcadia, California • Bakersfield, California • Beverly Hills, California + 57 more
- Conditions
- Leber Congenital Amaurosis (LCA), Retinitis Pigmentosa (RP)
- Interventions
- No treatment: retrospective chart review
- Other
- Lead sponsor
- QLT Inc.
- Industry
- Eligibility
- 8 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2016
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • Portland, Oregon
- Conditions
- Diabetic Macular Edema, Age-related Macular Degeneration
- Interventions
- MTP-131
- Drug
- Lead sponsor
- Stealth BioTherapeutics Inc.
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Retinitis Pigmentosa
- Interventions
- NAC effervescent tablets
- Drug
- Lead sponsor
- Johns Hopkins University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2030
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Rhegmatogenous Retinal Detachment, Proliferative Vitreoretinopathy
- Interventions
- Netarsudil 0.02% Ophthalmic Solution [RHOPRESSA], Glycerin 0.2%/Hypromellose 0.2%/Peg 1%/Soln,Oph,Ud
- Drug
- Lead sponsor
- Wills Eye
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Head and Neck Cancer, Kidney Cancer, Liver Cancer, Lymphoma, Neuroblastoma, Ovarian Cancer, Retinoblastoma, Sarcoma, Testicular Germ Cell Tumor
- Interventions
- filgrastim, carboplatin, thiotepa, topotecan hydrochloride, autologous bone marrow transplantation, bone marrow ablation with stem cell support, in vitro-treated bone marrow transplantation
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- Up to 21 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1992 – 2005
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Diabetic Macular Edema
- Interventions
- Experimental: Group 1 - 50mg RZ402, Experimental: Group 2 - 200mg RZ402, Experimental: Group 3 - 400mg RZ402, Placebo: Group 4 - Placebo
- Drug · Other
- Lead sponsor
- Rezolute
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 94 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 32
- States / cities
- Phoenix, Arizona • Bakersfield, California • Beverly Hills, California + 29 more
- Conditions
- Diabetic Macular Edema, Diabetic Retinopathy
- Interventions
- MS-R001 (rapamycin)
- Drug
- Lead sponsor
- Santen Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2008
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Arlington, Texas
- Conditions
- Glaucoma, Retinal Pathology
- Interventions
- Not listed
- Lead sponsor
- Mid-Atlantic Glaucoma Experts
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 200 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- Baltimore, Maryland
- Conditions
- Central Retinal Artery Occlusion
- Interventions
- KUS121 high dose, KUS121 low dose, Sham procedure
- Drug
- Lead sponsor
- Kyoto Drug Discovery and Development Co., Ltd.
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2025
- U.S. locations
- 11
- States / cities
- Encino, California • Huntington Beach, California • Oakland, California + 8 more
- Conditions
- Diabetic Retinopathy (DR)
- Interventions
- PRONTO-EYE
- Behavioral
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Macular Edema, Cystoid, Retinal Vein Occlusion
- Interventions
- Standard Care, intravitreal triamcinolone injection
- Other · Drug
- Lead sponsor
- The Emmes Company, LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 682 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2004 – 2009
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin
- Conditions
- Geographic Atrophy, Age-related Macular Degeneration
- Interventions
- RO7669330, Syfovre™, Izervay™
- Drug
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Sun City, Arizona • Beverly Hills, California + 14 more
- Conditions
- Usher Syndrome, Retinitis Pigmentosa
- Interventions
- SAR421869
- Drug
- Lead sponsor
- Sanofi
- Industry
- Eligibility
- 6 Years and older
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2019
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Diabetic Retinopathy, Vitreous Hemorrhage Due to Diabetes Mellitus
- Interventions
- Faricimab Injection, sham treatment
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- DIABETIC MACULAR EDEMA
- Interventions
- Triamcinolone acetonide, laser
- Drug · Procedure
- Lead sponsor
- University of Oklahoma
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2013
- U.S. locations
- 1
- States / cities
- Oklahoma City, Oklahoma
- Conditions
- Retinal Vein Occlusion
- Interventions
- Anecortave Acetate
- Drug
- Lead sponsor
- Manhattan Eye, Ear & Throat Hospital
- Other
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2002 – 2007
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Macular Edema
- Interventions
- abicipar pegol, ranibizumab, sham procedure
- Drug · Other
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 19 Years and older
- Enrollment
- 151 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 2
- States / cities
- Gilbert, Arizona • Abilene, Texas